OTCMKTS:INVVY Indivior (INVVY) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free INVVY Stock Alerts $21.85 -0.40 (-1.82%) (As of 06/9/2023) Add Compare Share Share Today's Range$21.64▼$21.8550-Day Range$21.85▼$21.8552-Week Range$14.76▼$35.50Volume8,100 shsAverage Volume3,825 shsMarket Capitalization$3.01 billionP/E Ratio20.81Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Indivior alerts: Email Address Ad Weiss RatingsThe only accurate crypto trading system I know …Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.Here's what our expert says you should buy before April 14. About Indivior Stock (OTCMKTS:INVVY)Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Read More INVVY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVVY Stock News HeadlinesApril 25, 2024 | uk.investing.comUK-listed drugmaker Indivior seeks shareholder nod for US listingApril 25, 2024 | lse.co.ukIndivior shares down despite profit boost on planned shift to New YorkApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 25, 2024 | marketwatch.comIndivior Confirms Intention to Move Primary Listing to U.S. From LondonApril 25, 2024 | finance.yahoo.comIndivior Confirms Plan to Switch Listing From London to New YorkApril 21, 2024 | ft.comPsychology class: Indivior aims to move primary listing from London to New YorkMarch 6, 2024 | finance.yahoo.comZacks.com featured highlights Modine Manufacturing, Indivior and InterfaceFebruary 22, 2024 | marketwatch.comIndivior Shares Jump on Possible U.S. Listing, Swing to Pretax ProfitApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 22, 2024 | msn.comIndivior shares soar as pharma firm ponders primary listing in the USFebruary 22, 2024 | msn.comDrug maker Indivior considers ditching primary UK listing for USFebruary 22, 2024 | uk.finance.yahoo.comUPDATE 1-UK-listed Indivior plans shifting to US bourses by summerFebruary 22, 2024 | ca.news.yahoo.comDrugmaker Indivior consults on moving primary listing from London to USFebruary 22, 2024 | finance.yahoo.comIndivior plans shifting primary listing to U.S.February 22, 2024 | ft.comIndivior aims to move primary listing from London to New YorkFebruary 22, 2024 | msn.comIndivior plans primary US listing in another hit to London’s flagging equity marketJanuary 16, 2024 | thetimes.co.ukIndivior boss brings promise of a pick-me-up for staffDecember 20, 2023 | marketwatch.comIndivior Resolves Patent Disputes With ActavisDecember 5, 2023 | lse.co.ukIndivior and Reckitt land legal boost in UK Suboxone claimDecember 5, 2023 | marketwatch.comIndivior Says UK High Court Strikes Claims Against It and Reckitt BenckiserNovember 17, 2023 | lse.co.ukIndivior to keep Scopia's Jerome Lande on board as agreement extendedNovember 17, 2023 | marketwatch.comIndivior Extends Relationship, Board Representation of Major ShareholderNovember 17, 2023 | lse.co.ukUPDATE: Indivior plans up to USD100 million share buyback programmeNovember 17, 2023 | marketwatch.comIndivior to Begin $100 Mln Share BuybackNovember 9, 2023 | uk.finance.yahoo.comIndivior Announces Q3 2023 Financial ResultsNovember 9, 2023 | lse.co.ukIndivior swings to quarterly loss on costs despite strong salesNovember 9, 2023 | marketwatch.comIndivior Swings to Pretax Loss on Higher Costs; Backs Revenue ViewSee More Headlines Receive INVVY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:INVVY Previous SymbolNASDAQ:INVVY CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio20.81 Forward P/E Ratio17.62 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$791 million Price / Sales3.81 Cash Flow$1.15 per share Price / Cash Flow18.94 Book Value$1.45 per share Price / Book15.07Miscellaneous Outstanding Shares137,880,000Free FloatN/AMarket Cap$3.01 billion OptionableNot Optionable Beta0.35 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMark CrossleyChief Executive Officer & Executive DirectorRyan PreblickChief Financial Officer & Executive DirectorChristian HeidbrederChief Scientific OfficerCynthia CetaniChief Compliance & Integrity OfficerNina DeLorenzoChief Global Impact OfficerKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRCrinetics PharmaceuticalsNASDAQ:CRNXXenon PharmaceuticalsNASDAQ:XENEIDEAYA BiosciencesNASDAQ:IDYABausch Health CompaniesNYSE:BHCView All Competitors INVVY Stock Analysis - Frequently Asked Questions How have INVVY shares performed in 2024? Indivior's stock was trading at $21.8455 at the start of the year. Since then, INVVY shares have increased by 0.0% and is now trading at $21.8455. View the best growth stocks for 2024 here. How do I buy shares of Indivior? Shares of INVVY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:INVVY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.